Skip to main content

Table 3 Outcomes of Anti-Cancer Chemotherapy (Anti-CCT) and Anti-MTB Chemotherapy

From: Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Characteristic

Patients

All

LC (SCLC/NSCLC)

CRC

Other

(n = 30)

(n = 15, 5/10)

(n = 10)

(n = 5)

Initial concurrent anti-CCT regimen, n

 Intensive cytotoxic regimen and targeted agenta

4

0

3

1

 Intensive cytotoxic regimenb

19

10 (5/5)

6

3

 Single targeted agentc

2

2 (0/2)

0

0

 Single cytotoxic agentd

5

3 (0/3)

1

1

Best response on anti-CCT after commencing concurrent chemotherapy, n

 CR

1

0

1

0

 PR

10

5 (4/1)

3

2

 SD

5

2 (0/2)

3

0

 PD

6

4 (0/4)

2

0

 NE

8

4 (1/3)

1

3

ORR (%)e

36.7

33.3 (80.0/10.0)

40.0

40.0

Main anti-MTB chemotherapy, n

 2HREZ/7HRf

15

8 (3/5)

4

3

 6HRE/6HRg

7

2 (0/2)

4

1

 Levofloxacin-based

8

5 (2/3)

2

1

Duration of anti-MTB treatment (days), median (range)

275.0 (72–637)

274.0 (90–469) [274 (183–469)/255 (90–310)]

259.0 (72–539)

368.0 (273–637)

Duration of concurrent chemotherapy (days), median (range)

157.5 (13–408)

117.0 (20–245) [93 (20–207)/121 (48–245)]

168.5 (13–408)

155.0 (51–376)

MTB treatment outcomes, n (%)

All

LC

CRC

Other

 Cured

20 (66.7)

10 (66.7)

6 (60.0)

4 (80.0)

 Completed

1 (3.3)

0

1 (10.0)

0

 Died

9 (30)

5 (33.3)

3 (30.0)

1 (20.0)

 Failed

0

0

0

0

 Not evaluated

0

0

0

0

Success (%)h

70.0

66.7

70.0

80.0

  1. Abbreviations CI confidence interval, CR complete response, CRC colorectal cancer, E ethambutol, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, H isoniazid, LC lung cancer, MTB Mycobacterium tuberculosis, NE not evaluable, ORR overall response rate, PD progressive disease, PR partial response, R rifampicin, SD stable disease, Z pyrazinamide
  2. aTwo cytotoxic agents combined with targeted therapy (bevacizumab or trastuzumab)
  3. bTwo cytoxic agents
  4. cErlotinib
  5. dSingle cytoxic agent (S-1, vinorelbine, or pemetrexed)
  6. eCR + PR
  7. fDaily drug combination containing HREZ for 2 months, followed by daily HR for 7 months
  8. gDaily drug combination containing HRE for 6 months, followed by HR for 6 months
  9. hCured + completed